|Bid||4.5800 x 21500|
|Ask||4.5900 x 27000|
|Day's range||4.5500 - 4.5952|
|52-week range||4.3000 - 7.5700|
|Beta (3Y monthly)||1.05|
|PE ratio (TTM)||9.47|
|Earnings date||25 Jan 2017 - 1 Feb 2017|
|Forward dividend & yield||0.16 (3.56%)|
|1y target est||6.04|
Oct.02 -- Banco Santander SA Chairman Ana Botin talks about hiring Andrea Orcel as the new chief executive officer. She speaks exclusively to Bloomberg's Francine Lacqua on "Bloomberg Markets."
November 16, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.
November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse.
November 6, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.
Bank investors seem to be spooked by Turkey, but they may be overreacting. That is one lesson you could draw from the share-price reactions to third-quarter results from two Spanish banks.
November 1, 2018 - Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.
The bank, based in Madrid, said it had earnings of 13 cents per share. The financial holding company posted revenue of $13.63 billion in the period. Its revenue net of interest expense was $13.63 billion, ...
Banco Santander SA’s (SAN.MC) third-quarter net profit grew strongly from a year earlier, when it reported a number of one-off charges. Net profit for the period rose roughly 36% to 1.99 billion euros ($2.
FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic.
Dengue fever is a debilitating disease typically leading to prolonged fever and severe joint pain. Dengue infection can progress unpredictably to a life-threatening form of the disease called dengue haemorrhagic fever that often requires hospitalized care. Today, there is no specific treatment available for dengue disease.
Oct 17 (Reuters) - Citigroup Inc: * CITIGROUP- ANZ, BANCO SANTANDER, BNP PARIBAS, CITI, DEUTSCHE BANK, HSBC, STANDARD CHARTERED ANNOUNCE JOINT INITIATIVE TO BUILD DIGITAL "TRADE INFORMATION NETWORK" ...
Seven banks, including HSBC and Banco Santander, have signed a Memorandum of Understanding (MoU) to create a global digital network in trade finance aiming at allowing cheaper and easier funding for corporates, a Santander manager said on Wednesday. The Australia and New Zealand Banking Group ANZ, BNP Paribas, Citibank, Standard Chartered and Deutsche Bank also agreed to join the digital trade information network expected to be operational by the third quarter of next year. "It is the first time that these banks come together to set a standard (...) that will allow cheaper access to finance because the risks are going to be reduced," Rogier Schulpen, global head of trade and working solutions at Banco Santander, said in a phone interview.
Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal.
Ripple said that xRapid, which uses the cryptocurrency XRP to carry out international transactions, is now commercially available.